Skip to content
DataLookout
Menu

MESI-HMNCT07900542

Middle East Study of Infections in Patients With Hematological Malignancies

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 5 words
    • Study description shortened, about 3 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall bloodstream infection incidence per 1,000 patient days
Timeframe: 30 days

Secondary (3)

Persistent bloodstream infection
Microbiological relapse
All-cause mortality

Arms and interventions

Bloodstream infection

Bloodstream infection

Other: No Intervention: Observational Cohort

Sites

9 sites in 5 countries

Saudi Arabia 4, United Arab Emirates 2, Jordan 1, Oman 1, Qatar 1